08 Sep 2022 Governance
Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II
On behalf of the Leukaemia UK team, Chair of Trustees, Chris Corbin OBE, has made the following statement:
“We are extremely saddened to hear the news of the death of Her Majesty Queen Elizabeth II. 
Together with the nation and people around the world, we remember a true leader who gave her life to duty. The Queen’s dedication, diligence and integrity were an inspiration to all and we are thankful for an inspiring monarch, who gave her life in service of her country and the Commonwealth.
The Queen’s support for the charity sector has enabled charities in the UK to thrive during her reign and will have a lasting impact for those whom the charities support.
We share our condolences with the entire Royal Family and especially the Queen’s children and grandchildren. Our thoughts are with them at this very difficult time.”
Related posts
29 February 2024
Nurse who made throwaway comment before blood cancer diagnosis welcomes new research boost into ‘Natural Killer’ cells
A former nurse, midwife, health visitor and NHS manager is welcoming new research into her particular blood cancer, after not recognising her mystery symptoms were leukaemia. Kay Cutting, from Seaham…
2 August 2023
Friends and family of Leicestershire woman who died from rare cancer campaign for more research and awareness
The family of a Leicestershire woman who died in July 2022, on the day of her leukaemia diagnosis, has raised over £17,000 in her memory to support Leukaemia UK. On…
6 June 2022
An open letter to people with a weakened immune system
Leukaemia UK joins the NHS and other charity leaders by signing an open letter, to encourage people with a weakened immune system to continue to book in or visit a walk-in centre for their Covid-19 vaccines.
10 January 2023
Clinical trial begins for pioneering new cancer treatment
Dr Konstantinos Tzelepis was awarded a Leukaemia UK research fellowship in 2020 and has developed a new class of cancer drug with the potential to treat leukaemia.